Etanercept: a tumor necrosis factor inhibitor for psoriasis and psoriatic arthritis

Authors: Gratch, Noah; Weinberg, Jeffrey M; Alexis, Andrew F

Source: Expert Review of Dermatology, Volume 1, Number 4, August 2006 , pp. 527-534(8)

Buy & download fulltext article:

Price: $73.00 plus tax (Refund Policy)

Abstract:

The first biological tumor necrosis factor (TNF)-α inhibitor to be approved for dermatological use is etanercept. Etanercept is a fusion protein that consists of the extracellular portion of the TNF-α receptor linked to the Fc portion of human immunoglobulin G. By binding to soluble and cell membrane-bound TNF-α, it has been shown to be effective in the treatment of many TNF-mediated inflammatory diseases. In the USA, etanercept has been approved by the FDA for use in rheumatoid arthritis (since 1998), psoriatic arthritis (since 2002), ankylosing spondylitis (since 2003), psoriasis (since 2004) and juvenile rheumatoid arthritis (since 2000). The use of etanercept as an approved and off-label therapeutic in dermatology is evaluated in this review. The safety issues related to the use of etanercept will also be reviewed.

Keywords: cytokine; etanercept; psoriasis; rheumatoid arthritis; tumor necrosis factor

Document Type: Research article

DOI: http://dx.doi.org/10.1586/17469872.1.4.527

Publication date: 2006-08-01

More about this publication?

Expert Review of Dermatology provides rapid publication of commentary and analysis on the latest research and clinical advances in all areas of dermatology, and of the challenges for this diverse specialty in a new medical era.
Editorial Board
Information for Authors
Submit a Paper
Subscribe to this Title
Information for Advertisers
Terms & Conditions
Information for Librarians
Free Trials
ingentaconnect is not responsible for the content or availability of external websites